Oxurion NV – Additional Topline Data from Positive Phase 1 Trial with THR-687 in Patients with Diabetic Macular Edema (DME)...
05 Febbraio 2020 - 7:00AM
Oxurion NV – Additional Topline Data from Positive Phase 1 Trial
with THR-687 in Patients with Diabetic Macular Edema (DME) to be
Presented at the Upcoming Angiogenesis, Exudation, and Degeneration
2020 Conference
Oxurion NV – Additional Topline Data from
Positive Phase 1 Trial with THR-687 in Patients
with Diabetic Macular Edema (DME) to be Presented
at the Upcoming Angiogenesis, Exudation, and Degeneration 2020
Conference
THR-687, a potent pan-RGD integrin
inhibitor, holds potential to become a new standard of care for
patients with DME
Leuven, Belgium, 5 February 2020 – 07.00
AM CET – Oxurion NV (Euronext Brussels: OXUR), a
biopharmaceutical company developing next generation therapies for
patients with diabetic eye disease, today announces that a
presentation of further data from a Phase 1 study with THR-687 in
patients with diabetic macular edema (DME) will be given at the
Angiogenesis, Exudation, and Degeneration 2020 conference being
held on February 8, 2020, in Miami, US.
The presentation will be made by Arshad Khanani,
M.D., M.A., Director of Clinical Research at Sierra Eye Associates,
Reno, Nevada, US, one of the investigators of the THR-687 Phase 1
study.
Details of the presentation are as
follows:
Title:
Results of a Phase 1 Study Using the Integrin Antagonist THR-687 in
Patients with DMEDate/time: February 8;
5.08 pm ESTSession title: Diabetes, Uveitis, and Retinal
Degenerations
END
For further information please
contact:
Oxurion NVWouter Piepers, Global Head of Investor Relations&
Corporate CommunicationsTel: +32 16 75 13 10 / +32 478 33 56
32wouter.piepers@oxurion.com |
Citigate Dewe Rogerson David Dible/ Sylvie Berrebi/Frazer HallTel:
+44 20 7638 9571oxurion@citigatedewerogerson.com |
About Oxurion
Oxurion (Euronext Brussels: OXUR) is a
biopharmaceutical company developing next generation standard of
care therapies, which are designed to better preserve vision in
patients with diabetic eye disease, the leading cause of blindness
in people of working age worldwide.
Oxurion’s clinical pipeline comprises:
- THR-149, a plasma kallikrein inhibitor being developed as a
potential new standard of care for DME patients who respond
sub-optimally to anti-VEGF
therapy. THR-149
has shown positive topline Phase 1 results for the treatment of
DME. The Company is currently preparing to conduct a Phase 2
clinical program, which is expected to start in H1 2020. THR-149
was developed in conjunction with Bicycle Therapeutics plc (NASDAQ:
BCYC)
- THR-687, is a pan-RGD integrin inhibitor, that is being
developed as a potential new standard of care for all DME
patients Positive
topline results in a Phase 1 clinical study assessing it as a
treatment for DME were announced in January 2020. THR-687 is
expected to enter a Phase 2 clinical trial in H2 2020. THR-687 is
an optimized compound derived from a broader library of integrin
inhibitors in-licensed from Galapagos nv (Euronext & NASDAQ:
GLPG).
Oxurion is headquartered in Leuven, Belgium, and is listed on
the Euronext Brussels exchange under the symbol OXUR.
More information is available at www.oxurion.com
Important information about
forward-looking statements
Certain statements in this press release may be
considered “forward-looking”. Such forward-looking statements are
based on current expectations, and, accordingly, entail and are
influenced by various risks and uncertainties. The Company
therefore cannot provide any assurance that such forward-looking
statements will materialize and does not assume an obligation to
update or revise any forward-looking statement, whether as a result
of new information, future events or any other reason. Additional
information concerning risks and uncertainties affecting the
business and other factors that could cause actual results to
differ materially from any forward-looking statement is contained
in the Company’s Annual Report. This press release does not
constitute an offer or invitation for the sale or purchase of
securities or assets of Oxurion in any jurisdiction. No
securities of Oxurion may be offered or sold within the United
States without registration under the U.S. Securities Act of 1933,
as amended, or in compliance with an exemption therefrom, and in
accordance with any applicable U.S. state securities laws.
Grafico Azioni Oxurion NV (EU:OXUR)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Oxurion NV (EU:OXUR)
Storico
Da Apr 2023 a Apr 2024